Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 7/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21053159 | 0.94 | MAPT (0.46) | MAPTAKR1C3AKR1C2EPHB2DDR1 | |
| SCHEMBL25791116 | 0.87 | NPSR1 (0.43) | MAPTPDK2AKR1C3AKR1C2EPHB2 | |
| SCHEMBL30061347 | 0.85 | ABCG2 (0.44) | MAPTPDK2AKR1C3AKR1C2BRD4 | |
| SCHEMBL21090761 | 0.85 | ABCG2 (0.44) | MAPTPDK2AKR1C3AKR1C2BRD4 | |
| SCHEMBL21054684 | 0.83 | AKR1C3 (0.47) | MAPTAKR1C3AKR1C2EPHB2DDR1 | |
| SCHEMBL21054916 | 0.81 | AKR1C3 (0.53) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL30061296 | 0.81 | AKR1C3 (0.53) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL30063461 | 0.81 | NPSR1 (0.52) | MAPTAKR1C3AKR1C2EPHB2DDR1 | |
| SCHEMBL21090661 | 0.81 | NPSR1 (0.52) | MAPTAKR1C3AKR1C2EPHB2DDR1 | |
| SCHEMBL21090762 | 0.80 | DDR2 (0.48) | MAPTAKR1C3AKR1C2EPHB2DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | MAPT 516/4885PDK2 3742/4885TYK2 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.